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regulator of ZAP-mediated retroviral restriction
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Abstract 
Background: Matrin 3 is a nuclear matrix protein involved in multiple nuclear processes. In HIV-1 infection, Matrin 3 
serves as a Rev cofactor important for the cytoplasmic accumulation of HIV-1 transcripts. ZAP is a potent host restric-
tion factor of multiple viruses including retroviruses HIV-1 and MoMuLV. In this study we sought to further character-
ize Matrin 3 functions in the regulation of HIV gene expression.
Results: Here we describe a function for Matrin 3 as a negative regulator of the ZAP-mediated restriction of retro-
viruses. Mass spectrometry analysis of Matrin 3-associated proteins uncovered interactions with proteins of the ZAP 
degradation complex, DDX17 and EXOSC3. Coimmunoprecipitation studies confirmed Matrin 3 associations with 
DDX17, EXOSC3 and ZAP, in a largely RNA-dependent manner, indicating that RNA is mediating the Matrin 3 interac-
tions with these components of the ZAP degradation complex. Silencing Matrin 3 expression caused a remarkably 
enhanced ZAP-driven inhibition of HIV-1 and MoMuLV luciferase reporter viruses. This effect was shared with addi-
tional nuclear matrix proteins. ZAP targets multiply-spliced HIV-1 transcripts, but in the context of Matrin 3 suppres-
sion, this ZAP restriction was broadened to unspliced and multiply-spliced RNAs.
Conclusions: Here we reveal an unprecedented role for a nuclear matrix protein, Matrin 3, in the regulation of ZAP’s 
antiretroviral activity. Suppressing Matrin 3 powers a heightened and broader ZAP restriction of HIV-1 gene expres-
sion. This study suggests that this ZAP regulatory mechanism is shared with additional nuclear matrix proteins.
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Background
Matrin 3 was first described as a major nuclear matrix 
protein and since has been associated with multiple 
nuclear processes [1]. The nuclear matrix is a proteina-
ceous structure that provides a dynamic spatial organi-
zation to the mammalian nucleus [2]. This matrix is 
defined as the nonhistone subnuclear fraction that is 
resistant to stringent biochemical procedures including 
high salt, detergent and nuclease treatment [3, 4] with a 
large proportion comprised of RNA-binding proteins [5]. 
Matrin 3 is a highly conserved 125 kDa inner matrix pro-
tein containing two RNA recognition motifs (RRM) that 
bind RNA [6, 7] and two zinc fingers that are predicted 
to bind DNA, displaying a diffuse predominantly nuclear 
localization and nucleolar exclusion [1, 8, 9]. Matrin 3 
has been involved in a variety of functions, such as medi-
ating neuronal cell death through its phosphorylation 
by PKA following NMDA receptor activation [10], and 
its role as a component of a p54nrb-PSF complex that 
anchors hyperedited nuclear dsRNAs to the nucleus to 
prevent the erroneous translation of potentially nonfunc-
tional mutant proteins [11]. In complex with p54nrb-
PSF, Matrin 3 has also been linked to early stages of the 
DNA double strand break response [12]. Matrin 3 has 
been implicated in DNA replication/repair, translation 
[9], chromatin organization [9, 13], and RNA stability 
and processing [7, 9], often through its interaction with 
proteins functioning in these processes. Additionally, 
Matrin 3 was also found to be an integral component of 
a dynamic scaffold aiding the organization of “nuclear 
functional neighborhoods” where proteins involved in 
chromatin replication and transcription are concentrated 
[14]. Clinically Matrin 3 has been linked as a cause of the 
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neurodegenerative disease familial amyotrophic lateral 
sclerosis (ALS), interacting with the RNA binding protein 
TDP-43, a protein that when mutated is known to cause 
ALS [15].
As a cellular protein target of viruses, Matrin 3 has 
been linked to both DNA and RNA viruses. Matrin 3 
was initially described as a common target of multiple 
alphaherpesviruses through a specific phosphoryla-
tion driven by the conserved US3 viral kinase [8]. Dur-
ing HIV-1 infection, it was demonstrated that Matrin 3 
binds HIV-1 RNAs [6] and acts as a Rev cofactor, pro-
moting the accumulation of Rev-dependent unspliced 
and singly-spliced HIV-1 RNAs [6, 16] in the cytoplasm. 
HIV-1 encodes nine proteins through strictly controlled 
splicing of viral RNA resulting in unspliced (Gag, Gag-
Pol), singly-spliced (Env, Vif, Vpr, Vpu), and multiply-
spliced (Tat, Rev, Nef) transcripts. Controlled levels of 
these transcripts are crucial to efficient HIV-1 replication 
[17]. Moreover, Matrin 3’s RRMs are necessary for its 
Rev-dependent RNA stabilization and expression of Gag 
protein [16]. These studies pointed out that this effect on 
Gag was likely at a post-transcriptional step, as Matrin 3 
levels did not seem to affect transcription [6, 16].
The host factor, CCCH-type Zinc-Finger Antiviral pro-
tein (ZAP) is a potent retroviral restriction factor that was 
originally discovered on the basis of its activity against 
Moloney MuLV (murine leukemia virus), and leads to 
the striking degradation of viral RNAs specifically in the 
cytoplasm [18]. Later studies revealed ZAP’s function as 
a restriction factor against many viruses including multi-
ple alphaviruses [19], the filoviruses Ebola and Marburg 
viruses [20], hepatitis B virus [21], and its ability to regu-
late murine gammaherpesvirus 68 latency [22]. ZAP does 
not act as a universal antiviral factor as some viruses such 
as herpes simplex virus type 1 and poliovirus were not 
affected by its expression [19]. Using MuLV vectors, ZAP 
was found to act through binding to viral RNAs [23] and 
recruiting the RNA processing exosome, a 3–5′ exoribo-
nuclease complex [24] and p72 DEAD box RNA helicase 
(DDX17) for optimal RNA degradation [25, 26]. ZAP 
also restricts replication of HIV-1 [27]. Further studies 
demonstrated that ZAP activity is directed principally to 
multiply-spliced HIV-1 RNAs through the utilization of 
3′–5′ RNA degradation machinery, while also recruiting 
components of the cellular decapping complex through 
p72 to degrade RNA through 5′–3′ exoribonuclease Xrn1 
[27]. Furthermore it was found that ZAP induces trans-
lational repression through its interaction with eIF4A, 
and this disruption of translation initiation is required for 
degradation of HIV-1 RNAs to occur [28].
In this study we find an unexpected role for Matrin 3 
as a regulator of the antiviral activity of ZAP. We dem-
onstrate that Matrin 3 interacts with key components of 
the RNA degradation machinery, and that suppression of 
Matrin 3 expression greatly enhances ZAP antiviral activ-
ity against HIV-1 RNAs. Importantly, loss of Matrin 3 in 
conjunction with ZAP expression broadens the restric-
tive activity to drive the degradation of both unspliced 
and multiply spliced HIV-1 transcripts. These result sug-
gest that Matrin 3 is a negative regulator of ZAP.
Results
Matrin 3 interacts with components of the ZAP 
degradation machinery in an RNA‑dependent manner
To explore the role of Matrin 3 in HIV-1 replication, we 
screened for Matrin 3 interacting proteins in both HIV-
1-infected and uninfected cells. Cell lysates were pre-
pared from uninfected human brain microglial CHME3 
[29], or CHME3 infected with a VSV-G pseudotyped 
HIV-1 vector pnl4.3env-luc+ (HIV-luc) using mild deter-
gent conditions. CHME3 cells were used in these experi-
ments as being highly permissive for HIV-1 replication 
and representative of microglial cells naturally infected 
by HIV-1 [30]. Endogenous Matrin 3 was then recov-
ered by immunoprecipitation and bound proteins were 
identified by mass spectrometric analysis. Many Matrin 
3-interacting proteins were identified in both unin-
fected and infected cells (listed in Table 1a), and a num-
ber of proteins were identified only in HIV-luc infected 
CHME3 (Table  1b). DDX17 and EXOSC3 were note-
worthy as known components of the RNA degradation 
machinery recruited by the retroviral restriction factor, 
ZAP, appearing only in infected CHME3 cells. DDX17 
is a cofactor of ZAP and an RNA helicase needed for 
optimal ZAP-mediated degradation of RNA, possibly 
through the restructuring of the secondary structure of 
ZAP-responsive mRNA elements [26]. DDX17 encodes 
two isoforms: p82 and a faster migrating p72 resulting 
from the use of different in-frame translation initiation 
codons. EXOSC3 is a core component of the human 
exosome complex responsible for 3’-5’ exoribonuclease 
activity [31].
To confirm that DDX17 and EXOSC3 interacted with 
Matrin 3, we tested for their coimmunoprecipitation with 
endogenous Matrin 3 in uninfected or infected 293Trex-
hZAP2 cells, a 293T cell line derivative in which doxy-
cycline induces the expression of myc-tagged ZAP2, a 
functional human isoform truncated at the C-terminus. 
Additionally we tested for interaction with the central 
factor of this complex, ZAP. 293TrexhZAP2 cells were 
infected with a HIV-luc reporter virus and then treated 
with doxycycline at 2  h postinfection, and lysates were 
prepared 48 h after infection. Matrin 3 coimmunprecipi-
tated with DDX17 with partial preference for the faster 
migrating p72 isoform, but not with the control GAPDH 
(Figure  1a). The association was partially disrupted by 
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treatment with RNAse A. Matrin 3 also interacted with 
EXOSC3 (Figure  1b) and ZAP (Figure  1c) in a strongly 
RNA-dependent manner. Similar results were also 
obtained in TE671 cells (data not shown). This interac-
tion of Matrin 3 with essential components of the RNA 
degradation machinery was observed in uninfected cells 
and with no apparent increase following HIV-luc infec-
tion. HIV-luc infection did not increase protein levels of 
DDX17, EXOSC3, or myc-ZAP2.
Matrin 3 suppression enhances ZAP‑mediated restriction 
of retroviral infection
The observation that Matrin 3 was associated with mul-
tiple proteins essential to the restriction involved in 
degrading HIV-1 mRNAs raised the possibility of a func-
tional involvement. To test if Matrin 3 had a role in the 
ZAP-mediated restriction of HIV-1, we overexpressed 
ZAP to restrict HIV-1 replication in HIV-luc infected 
293TrexhZAP2 cells, and tested for ZAP restriction 
activity with and without knockdown of Matrin 3. We 
found that ZAP alone induced an approximately sixfold 
restriction of HIV-1 Nef-luc expression in these cells, and 
that Matrin 3 knockdown alone led to a fourfold inhibi-
tion of HIV-1 Nef-luc expression. Since this reporter 
is Rev-independent, this effect is likely separate from 
Matrin 3’s function as a Rev cofactor, but may reflect 
the broad role of Matrin 3 in affecting mRNA process-
ing and expression. Remarkably, knockdown of Matrin 
3 expression in the context of ZAP overexpression led 
to a profound increase in ZAP-mediated HIV-1 restric-
tion, resulting in a 35-fold restriction (Figure  2a). HR’-
CMV-luc has a large portion of the HIV genome deleted 
and has previously been shown to be insensitive to ZAP 
restriction [27]. Infection with HR’-CMV-luc showed 
very modest reductions under all conditions tested, dem-
onstrating that Matrin 3 knockdown in the context of 
ZAP overexpression was not causing a global decrease of 
newly expressed luciferase reporter (Figure  2a). Similar 
Table 1 Proteins identified as Matrin 3 interacting proteins by mass spectrometry
Name Synonyms Accession #
(a) Identified as Matrin 3 interacting proteins in uninfected and infected cells
 Matrin 3* MATR3, KIAA0723 P43243
 Probable ATP-dependent RNA helicase DDX5 DDX5, G17P1, HELR, HLR1 P17844
 Heterogeneous nuclear ribonucleoproteins A2/B1* ROA2, HNRNPA2B1 P22626
 ATP-dependent RNA helicase DDX3X DDX3X, DDX3, DBX, O00571
 Heterogeneous nuclear ribonucleoprotein U HNRPU, HNRNPU SAFA, U21.1 Q00839
 Polypyrimidine tract-binding protein 1 PTBP1, PTB P26599
 Heterogeneous nuclear ribonucleoproteins C1/C2* HNRPC, HNRNPC P07910
 Heterogeneous nuclear ribonucleoprotein M HNRPM, HNRNPM, NAGR1 P52272
 Heterogeneous nuclear ribonucleoprotein A1 ROA1, HNRPA1, HNRNPA1 P09651
(b) Identified as a Matrin 3 interacting protein in infected cells alone
 Probable ATP-dependent RNA helicase DDX17* DDX17, RNA-dependent helicase p72 Q92841
 ATP-dependent DNA helicase RECQ1, RECQL1 P46063
 Tubulin alpha-1A TBA1A, TUBA3 Q71U36
 Tubulin beta-2C chain TBB2C, TUBB2C, TUBB4B P68371
 Cellular tumor antigen p53 P53, TP53 P04637
 Heterogeneous nuclear ribonucleoprotein R HNRPR, HNRNPR O43390
 Histone H1.2 H12, HIST1H1C, H1F2 P16403
 Plasminogen activator inhibitor 1 RNA-binding protein PAIRB, PAIRBP1, SERBP1 Q8NC51
 Heterogeneous nuclear ribonucleoprotein K HNRPK, HNRNPK P61978
 Tubulin beta-6 chain TBB6, TUBB6 Q9BUF5
 Tropomyosin alpha-1 chain TPM1, C15orf13, TMSA P09493
 60S ribosomal protein L7 RL7, RPL7 P18124
 Exosome complex component RRP40 EXOS3, EXOSC3, RRP40 Q9NQT5
 SAFB-like transcription modulator SLTM, MET Q9NWH9
 60S ribosomal protein L15 RL15, EC45 P61313
 ELAV-like protein 1 ELAV1, ELAVL1, HUR Q15717
 60S ribosomal protein L18 RL18, RPL18 Q07020
 Heterogeneous nuclear ribonucleoprotein A3 ROA3, HNRNPA3, HNRPA3 P51991
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experiments were performed with infection with HIV-1 
at three dilutions of virus (1:2 to 1:200), and a 35-fold 
restriction on average was seen at all virus dilutions (data 
not shown). To determine if this finding was HIV-1-spe-
cific, we also tested for the effects of Matrin 3 suppres-
sion on ZAP-mediated inhibition of Moloney murine 
leukemia virus (MoMuLV) expression. We observed a 
less dramatic but significant enhancement of ZAP-driven 
retroviral restriction. Matrin 3 KD or ZAP overexpres-
sion individually caused a twofold inhibition of virus 
expression, while the combination of both together led 
to a sixfold inhibition (Figure 2b). Western blots showed 
that the knockdown of Matrin 3 and the overexpression 
of myc-ZAP2 were both achieved at high efficiency (Fig-
ure 2c). Conversely, we tested if overexpression of Matrin 
3 would hinder ZAP activity. Myc-DDK tagged Matrin 3 
was transiently expressed in 293TrexhZAP2 cells. Doxy-
cycline was added to drive ZAP expression, the cells 
were then infected with HIV-Luc at two different dilu-
tions, and lysates were collected 2  days postinfection. 
Exogenous overexpression of Matrin 3 decreased ZAP’s 
restrictive activity by approximately half at both dilutions 
Figure 1 Matrin 3 interacts with components of the ZAP degradation machinery. a Matrin 3 interacts with DDX17. 293TrexhZAP2 cells were 
infected with HIV-luc (+) or mock infected (−) followed by doxycycline treatment at 200 ng/ml. Cells were then lysed in the presence (+) or 
absence (−) of RNAse A (50 µg/ml). Lysates were subjected to immunoprecipitation for endogenous Matrin 3 using rabbit α- Matrin 3 or α- control 
Ig. DDX17, GAPDH, b EXOSC3, or c myc-ZAP2 were detected with antibodies indicated.
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(Figure  2d). Although not as striking as the effects on 
ZAPs activity during Matrin 3 suppression, the data are 
consistent with the concept that Matrin 3 impedes ZAP 
activity. Taken together, our data suggests that Matrin 3 
is a negative regulator of ZAP-mediated restriction activ-
ity on retroviruses.
Effects of other major nuclear matrix proteins on ZAP 
activity
Earlier studies indicated that Matrin 3 is one of a col-
lection of major nuclear matrix proteins that create a 
nuclear scaffold affecting a diverse array of cellular func-
tions including RNA processing. To explore the poten-
tial involvement of this group of matrix proteins on ZAP 
function, we tested the nuclear matrix proteins het-
erogeneous nuclear ribonucleoprotein U (HNRNPU), 
splicing factor proline/glutamine rich (polypyrimidine 
tract-binding protein-associated) (SFPQ), and lamin A/C 
for their effects on HIV-1 infection. These proteins have 
all been found as components of the nuclear matrix, an 
operationally defined fibrogranular nuclear subfraction 
[3–5, 32, 33]. HNRNPU [9, 34] and SFPQ [11, 12] are 
reported to form complexes with Matrin 3. Silencing of 
these nuclear proteins individually had modest effects 
on HIV-1 Nef-luc expression ranging from a 1.5-fold 
(for lamin A/C), up to a 3.9-fold effect (for HNRNPU) 
(Figure  3a). Notably, silencing of HNRNP U or SFPQ, 
but not lamin A/C, together with ZAP overexpression, 
led to enhanced ZAP restriction of HIV. While ZAP 
overexpression alone resulted in a 5.6-fold restriction, 
ZAP overexpression along with knockdown of HNRN-
PUKD or SFPQ increased the restriction to approxi-
mately 30-fold (Figure 3a). No significant increase in ZAP 
function was detected with knockdown of lamin A/C. 
▸
Figure 2 Matrin 3 suppression enhances ZAP-mediated restriction 
of retroviral infection. a Enhanced ZAP-mediated HIV-1 restriction in 
the absence of Matrin 3 expression. 293TrexhZAP2 cells (Ctrl) or cells 
silenced for Matrin 3 expression (Matrin 3 KD) were infected with HIV-
luc or HR’-CMV-luc then treated with (ZAP) or without doxycycline 
treatment at 200 ng/ml. Cells were then harvested 2 days postin-
fection and lysates were subjected to luciferase assays to measure 
Nef-luc reporter activity. Data presented are the mean RLU/mg values 
of at least three experiments done in triplicate ±SD. Fold restriction 
was calculated from dividing Ctrl siRNA values by the results of each 
treatment indicated. b MoMuLV restriction also improved by Matrin 3 
silencing. Data presented are the mean RLU/mg values of three inde-
pendent experiments done in triplicate. P values ≤0.05 are shown. c 
Knockdown of Matrin 3 by siRNA treatment. Lysates from a represent-
ative experiment were subjected to immunoblot to illustrate Matrin 
3 knockdown. Lysates were analyzed for at least three independent 
experiments. 293TrexhZAP2 were treated with control siRNA (siCtrl) 
or siRNA to Matrin 3 (siMatrin 3) for two consecutive days followed 
by infection and doxycycline treatment as stated above. Induc-
tion of myc-ZAP2 overexpression was detected with mouse α-myc 
antibody. GAPDH is the protein loading the control. d Cells transiently 
expressing mycDDK-tagged Matrin 3 (MDM3) or vector alone (MD) 
were infected with HIV-luc at two different dilutions, then treated 
with (ZAP) or without doxycycline (Dox) treatment at 200 ng/ml. Cells 
were then harvested as stated above. Data presented are the mean 
RLU/mg values of two experiments done in triplicate. Fold restriction 
was calculated from dividing MD values by the results of each treat-
ment indicated for each dilution.
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Infection with HR’-CMV-luc showed very modest reduc-
tions under all conditions. This finding suggest a role for 
at least three nuclear matrix proteins in negatively regu-
lating ZAP-mediated restriction of HIV-1 gene expres-
sion. A similar trend was noted in MoMuLV infection 
(Figure  3b). Silencing of matrix proteins alone showed 
only very subtle effects on restriction. ZAP overexpres-
sion alone caused a 2-fold restriction, while overexpres-
sion in Matrin 3 KD and SFPQ KD cells demonstrated 
a 5-fold restriction and overexpression in HNRNPU KD 
cells showed an 11-fold restriction. No such increase was 
seen in lamin A/C KD cells. These observations suggest 
that multiple nuclear matrix proteins can negatively reg-
ulate ZAP restriction of multiple viruses.
Matrin 3 knockdown enhances the ZAP‑induced 
degradation of HIV‑1 transcripts
Both Matrin 3 and ZAP are known to have effects on 
HIV-1 mRNA levels that are specific to particular splic-
ing classes of mRNAs. Matrin 3 is necessary for the accu-
mulation of Rev-dependent unspliced and singly-spliced 
transcripts in the cytoplasm and has been documented 
to act as a cofactor of Rev [6, 16]. ZAP targets most 
strongly multiply-spliced transcripts for degradation, 
and has smaller effects on unspliced and singly-spliced 
mRNAs [27]. To investigate which HIV-1 RNA tran-
scripts were the target of the augmented ZAP restriction 
upon Matrin 3 knockdown, we used qRTPCR to monitor 
RNA levels upon ZAP expression, Matrin 3 knockdown, 
or both. Following RNA extraction of HIV-luc infected 
293TrexhZAP2 cells, we quantified unspliced (Figure 4a) 
and multiply-spliced transcripts (Figure  4b). In whole 
cell extracts (WCE), unspliced mRNA was reduced by 
approximately 8-fold with Matrin 3 KD and 6-fold with 
ZAP overexpression, and by approximately 12-fold with 
both (Figure 4a). Multiply-spliced RNA levels (Figure 4b) 
were reduced approximately 11-fold with Matrin 3 KD 
or 8-fold with ZAP overexpression. Together, however, 
these conditions led to a considerably greater 34-fold 
reduction in multiply-spliced mRNAs. The level of HIV-1 
fold reduction in multiply-spliced (Nef-luc) RNA lev-
els with both Matrin 3 KD and ZAP overexpression was 
similar to that observed for Nef-luc protein expression in 
luciferase experiments (Figure  2a), strongly suggesting 
that Matrin 3 inhibits the ZAP-mediated degradation of 
HIV-1 RNAs.
Previously it was found that ZAP specifically elimi-
nated MoMuLV RNA in the cytoplasm, and not the 
Figure 3 Effects of other major nuclear matrix proteins on zap activity. Distinct nuclear matrix proteins regulate ZAP effects on a HIV-1 or HR’-
CMV-luc and b MoMuLV. 293TrexhZAP2 cells were transfected with control siRNA (Ctrl) or siRNA against Matrin 3 (Matrin 3 KD), HNRNPU (HNRNPU 
KD), SFPQ (SFPQ KD), or Lamin A/C (Lamin A/C KD) for two consecutive days. Subsequently on the following day, cells were infected with HIV-luc 
or HR’-CMV-luc then treated with (ZAP) or without doxycycline treatment at 200 ng/ml. Cells were then harvested 2 days postinfection and lysates 
were subjected to luciferase assays to measure Nef-luc reporter activity. Fold restriction was calculated from dividing Ctrl siRNA values by the results 
of each treatment indicated. Data presented are the mean RLU/mg values of three independent experiments done in triplicate ±SD (HIV and 
MoMuLV) and two experiments done in triplicate ±SD for HR’-CMV-luc. Statistical analyses were done to test for differences between ZAP and ZAP 
induced in cells treated with siRNA. P values ≤0.05 are shown.
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nucleus [18]. Whether a similar compartmentalization 
for RNA elimination for other ZAP-sensitive viruses is 
yet to be defined. To determine if the observed reduc-
tion in HIV-1 transcript levels were restricted to a 
subcellular compartment, mRNA levels were meas-
ured in nuclear and cytoplasmic fractions. Unspliced 
mRNA in nuclear fractions was reduced in Matrin 3 
KD cells or with ZAP overexpression, and these con-
ditions together produced a larger 18-fold reduction 
in mRNA levels. Comparable reductions in unspliced 
mRNAs were observed in the cytoplasmic fraction, 
with Matrin 3 KD and ZAP overexpression together 
resulting in a 13-fold reduction (Figure  4a). Matrin 3 
KD or ZAP overexpression individually led to similar 
reductions of the multiply-spliced mRNAs in both the 
nucleus and cytoplasmic fractions, while together these 
conditions lead to a remarkable 24-fold reduction and 
57-fold reduction in RNA levels in the nuclear and cyto-
plasmic compartments respectively (Figure 4b). Cellular 
genes beta-glucuronidase (GUSB) and small Nuclear 
Ribonucleoprotein 70  kDa (U1) were not substantially 
affected under any conditions, suggesting that Matrin 
3 KD and ZAP overexpression together was not caus-
ing global reductions in RNA levels (Figure 4c.) To test 
for the effectiveness of the fractionation, the distribu-
tion of tubulin was examined by Western blot. Tubulin 
was located chiefly in the cytoplasmic fraction, showing 
that there was efficient separation of these subcellular 
compartments (Figure  4d). Visualization of myc-ZAP2 
following fractionation showed that at steady state ZAP 
localized predominantly to the cytoplasmic fractions 
(Figure 4d) as noted in past studies of the rat homolog of 
ZAP [35]. Western blots for Matrin 3 showed predomi-
nant localization to the nucleus, but with some localiza-
tion to the cytoplasm. These localizations are consistent 
with the observations that the changes in RNA levels 
are happening in both cytoplasm and nucleus. Quan-
tification of Matrin 3 RNA showed no effect of HIV-1 
infection or ZAP overexpression on Matrin 3 RNA lev-
els (data not shown).
Taken together these results indicate that although 
knockdown of Matrin 3 or overexpression of ZAP 
alone can decrease HIV-1 mRNAs levels, when ZAP is 
▸Figure 4 Matrin 3 knockdown improves the ZAP-induced degra-
dation of HIV-1 transcripts. Greater unspliced and multiply-spliced 
RNA degradation with simultaneous ZAP induction and Matrin 3 
knockdown. 293TrexhZAP2 cells were transfected with control siRNA 
(Ctrl) or siRNA against Matrin 3 (Matrin 3 KD) for two consecutive 
days. The following day cells were infected with HIV-luc then treated 
with doxycycline treatment at 200 ng/ml (ZAP) or without. Two days 
postinfection, RNA was isolated from whole cell extracts (WCE), as well 
as from nuclear and cytoplasmic compartments. QRT-PCR analysis was 
performed on HIV-1 RNA using specific primers against a unspliced 
transcripts (Gag) and b multiply-spliced transcripts (Nef ). Relative lev-
els of these transcripts normalized to GAPDH levels are presented. Fold 
restriction was calculated from dividing Ctrl siRNA values by the results 
of each treatment indicated within the WCE, nuclear, or cytoplasmic 
compartment measured. Data presented are from a representative 
experiment done in triplicate. Similar results were obtained for three 
independent experiments. c QRT-PCR analysis of WCE RNA using 
specific primers against cellular transcripts, beta-glucuronidase (GUSB), 
Small Nuclear Ribonucleoprotein 70 kDa (U1), or HIV-1 Nef-luc. Fold 
restriction was calculated as above. Similar results were obtained for 
two independent experiments. d An immunoblot of the cytoplasmic 
(Tubulin) and nuclear fractions (Matrin 3). Compartmentalization of 
myc-ZAP2 is also shown.
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overexpressed in the context of Matrin 3 KD a drasti-
cally enhanced reduction of both unspliced and multi-
ply-spliced HIV-1 transcripts occurs. This suggests that 
Matrin 3 is negatively regulating ZAP-mediated HIV-1 
restriction and may be serving in a HIV-1 RNA protec-
tive function. Furthermore, this effect is noted in both 
nuclear and cytoplasmic compartments, and most prom-
inently for multiply-spliced transcripts.
Discussion
Matrin 3 is a host cell protein involved in the replica-
tion cycle of multiple viruses [6, 8, 16]. In HIV-1 infec-
tion, Matrin 3 was shown to act as a Rev cofactor and 
promotes the accumulation of HIV-1 unspliced and sin-
gly-spliced transcripts in the cytoplasm [6, 16]. Here we 
demonstrate that Matrin 3 associates with three key pro-
teins of the ZAP degradation complex and that silencing 
of Matrin 3 expression causes a remarkable increase in 
ZAP’s restriction of retroviral transcripts. Thus our data 
show that Matrin 3 serves as a negative regulator of ZAP.
Intriguingly, many of the proteins identified by mass 
spectrometry as binding to Matrin 3 (Table 1) were RNA 
binding proteins involved in mRNA processing and 
transport. DEAD-box proteins such as DDX17, many 
of which are putative helicases [36], function in vari-
ous RNA-mediated processes. Another family of bind-
ing proteins, the HNRNPs, are highly abundant nuclear 
RNA-binding proteins that are amongst the core pro-
teins that bind and package recently transcribed nascent 
nuclear pre-mRNAs into ribonucleoprotein complexes, 
and also play important roles in constitutive and alter-
native splicing. HNRNPs are involved in both DNA and 
RNA metabolism, often through their recruitment of 
regulatory proteins involved in these processes. Addi-
tionally HNRNPs may remain bound to pre-mRNAs as 
chaperones or regulators through their RNA biogenesis 
and later maturation in the cytoplasm [37, 38].
A first indication that Matrin 3 held a role in the 
ZAP degradation complex was its binding to DDX17 
and EXOSC3. The mass spectrophotometric analy-
sis of Matrin 3-associated proteins repeatedly identi-
fied DDX17 and EXOSC3, both integral components of 
the ZAP degradation machinery. Matrin 3 interacted 
with these proteins in a largely RNA-dependent manner 
at endogenous levels (Figure  1a, b). Additionally myc-
tagged ZAP2 bound to Matrin 3 in an RNA-dependent 
(i.e. RNase-sensitive) manner. As RNAs are involved in 
bridging the proteins, one model for the mechanism of 
Matrin 3’s regulation of ZAP’s antiviral activity may be 
through competition for similar sites on viral RNAs. Its 
interactions with proteins of the complex may reveal a 
dynamic competition for sites on targeted cellular and/or 
viral RNAs.
We found that loss of Matrin 3 expression alone had 
significant effects on HIV-1 RNA levels. Matrin 3 silenc-
ing caused HIV-1 transcripts levels to drop well below 
those of controls (Figure 4a, b). A number of RNA bind-
ing proteins (RBPs) important to HIV-1 RNA processing 
and export, such as DDX3, DDX5, DDX17, and PTBP1 
[26, 27, 39–43] were identified in our screen (Table  1), 
and thus it is plausible that Matrin 3 is providing a scaf-
fold for proper RBP assembly on HIV-1 RNA transcripts. 
Many of these proteins were also identified as Matrin 
3-associating proteins in a previous mass spectrometry 
analysis using exogenously expressed Matrin 3 [7]. More-
over, a yeast two hybrid analysis identified SLTM, DDX5 
[9] and PTBP1 [16] as Matrin 3-associating proteins. 
HNRNPU and Matrin 3 have been proposed to serve as a 
scaffold at sites of DNA replication and transcription due 
to their colocalization within dynamic nuclear microen-
vironments [14]. Hence, these interactions support the 
idea that Matrin 3 is acting in complex with key RNA-
binding proteins to regulate various processes to ensure 
the proper maturation, transport and transcript levels of 
both host and viral transcripts.
The overexpression of ZAP in the context of Matrin 3 
suppression caused the most marked decrease in HIV-1 
transcript levels, far exceeding the decrease seen in 
either condition alone. ZAP as reported previously sub-
stantially lowered levels of HIV-1 transcripts especially 
multiply spliced transcripts, but when endogenous levels 
of Matrin 3 were lowered, the magnitude of the reduc-
tion was increased, and was extended to both unspliced 
and multiply spliced HIV-1 transcripts. Furthermore 
our study suggests that Matrin 3’s negative regulation of 
ZAP may extend to the restriction of other ZAP-sensitive 
viruses (Figures 2b, 3b). We theorize that at endogenous 
levels, Matrin 3 provides a baseline inhibition of ZAP-
mediated degradation that for HIV-1 may begin in the 
nucleus and continue into the cytoplasm. Alternatively, 
this negative regulation may reflect Matrin 3 involve-
ment in exclusive restriction pathways in these subcel-
lular compartments. Removal of Matrin 3 augments 
and broadens ZAP’s ability to inhibit HIV-1 infection—
exposes the RNAs to attack by ZAP—and in effect leads 
to a more potent retroviral restriction factor.
Matrin 3 is known to interact with Rev, and operates as 
its cofactor to aid the expression of unspliced and singly-
spliced transcripts but not Rev-independent multiply-
spliced transcripts. Rev functions to inhibit the splicing 
and/or nuclear retention brought on by cis-repressor 
sequences in unspliced and singly-spliced transcripts 
[44]. However our findings indicate that Matrin 3’s effect 
on ZAP activity is likely a Rev-independent process, as a 
similar trend was seen with Rev-independent reporters, 
and with MoMuLV (Figure  2b) which does not express 
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Rev. Loss of Matrin 3 expression may lead unspliced 
and multiply-spliced transcripts to be retained in the 
nucleus and more vulnerable to nuclear and/or cytoplas-
mic RNA degradation. It is known that RBPs recruited 
during transcription can compete and therefore protect 
nascent RNAs from nuclear RNA surveillance machinery 
[38]. Hence, Matrin 3 may be functioning as an RBP in a 
RNA protective role. This function expands on the role 
of Matrin 3 not only as a Rev cofactor, important for the 
accumulation of unspliced and singly-spliced transcripts 
in the cytoplasm [6, 16], but also in the regulation of 
ZAP-mediated restriction of HIV-1 gene expression.
Transcription, splicing, localization and decay are often 
all interconnected steps in the course of RNA maturation 
[38]. The regulatory RBPs functioning in these roles may 
bind to nascent RNA and during their synthesis “config-
ure” them with the necessary RBP’s and other host pro-
teins needed for the proper packaging, transport and 
processing of the transcript. Matrin 3 has been proposed 
to act as a scaffold at active sites of transcription [14], and 
to interact with key proteins involved in RNA metabo-
lism. The absence of Matrin 3 may have direct effects on 
the assembly of necessary proteins for both cellular and 
viral RNA maturation, and improper packaging of tran-
scripts may have negative effects on their overall matu-
ration and stability. Further evidence for Matrin 3 acting 
to provide RNA stability for cellular and viral transcripts 
has been supported by our findings here and in previous 
studies where it was established to bind and control the 
stability of host cell RNA [7]. Matrin 3 has independently 
been suggested to function as an RBP positively regulat-
ing mRNA stability [45]. Other nuclear matrix proteins 
which are also RNA binding proteins involved in RNA 
metabolism display a commonality as to their effects 
on ZAP-mediated retroviral restriction, as seen for 
HNRNPU and SFPQ (Figure 3). Hence our studies reveal 
that this negative regulation of ZAP restriction may be a 
shared function of other nuclear matrix RBPs.
Future studies will be directed at finding in more detail 
how Matrin 3 is involved in regulating ZAP-mediated 
restriction of retroviruses. As Matrin 3 has been found 
to bind to both host and viral RNAs, Matrin 3 may com-
pete with ZAP for access to ZAP recognition motifs on 
HIV-1 RNAs, and thus suppression of Matrin 3 may leave 
both unspliced and multiply spliced transcripts further 
accessible to ZAP degradation machinery. ZAP mol-
ecules interact [46] and form dimers on ZAP-sensitive 
RNAs [47], and hence another possibility is that Matrin 
3 is inhibiting ZAP from properly dimerizing on HIV-1 
RNAs. Binding of Matrin 3 to DDX17, EXOSC3, and 
ZAP in uninfected cells may reflect a role for Matrin 3 
in alternate host RNA processes, but during infection 
Matrin 3 may impede ZAP from interacting with these 
proteins which are needed for optimal RNA degradation 
activity. Our study offers new insights into a function for 
Matrin 3 in the regulation of an HIV-1 restriction factor 
and expands on the potential for Matrin 3 in controlling 
HIV-1 gene expression.
Conclusions
Matrin 3, a matrix protein involved in multiple nuclear 
process, is important for the accumulation of unspliced 
and singly-spliced HIV-1 transcripts. ZAP is a retroviral 
restriction factor that leads to the degradation of largely 
multiply-spliced HIV-1 transcripts. Here we demonstrate 
that Matrin 3 interacts with key proteins of the ZAP-
degradation complex, and suppression of Matrin 3 dras-
tically improves ZAPs ability to block HIV-1 infection, 
with similar findings for MoMuLV. Silencing of Matrin 3 
also broadens ZAPs ability to degrade multiple classes of 
HIV-1 RNA. Our result supports the concept that Matrin 
3 impedes ZAP-mediated retroviral RNA degradation. 
As Matrin 3 is a highly conserved protein, this Matrin 3 
regulation of ZAP antiviral activity may extend to other 
ZAP-sensitive viruses.
Methods
Cell culture, transfections, plasmids, virus packaging 
and infections
293TrexhZAP2 cells have been previously described [27]. 
Briefly 293Trex cells (Invitrogen) were stably transfected 
with a tetracycline-inducible myc-tagged hZAP-v2, an 
alternatively spliced form of ZAP that differs at the C ter-
minus. CHME3, a human microglial cell line kindly pro-
vided by Dr. Mojgan Naghavi, Northwestern University 
were maintained in DMEM (Dulbecco’s Modified Eagle 
Medium) supplemented with 10% fetal bovine serum, 
Sodium Pyruvate, l-Glutamine, and Penicillin–Strepto-
mycin (Gibco).
Matrin 3 tagged at the C-terminus with MycDDK was 
generated from a commercial plasmid of matrin 3 gene 
(pCMV SPORT 6, Invitrogen) that was PCR ampli-
fied with oligonucleotides Matrin 3F (5′-GAGGCG 
ATCGCATGTCCAAGTCATTCCA-3′) and Matrin 3R 
(5′-GCGACGCGTAGTTTCCTTCTTCTGTCT-3′) 
using KOD Hot Start DNA Polymerase (Novagen). The 
PCR fragment was digested with Mlu1and AsiS1 and 
inserted into a MycDDK vector (Origene). MycDDK 
empty vector was generated by digesting a MycDDK 
tagged ORF clone with Xho1 and Sal1 followed by reli-
gation of the vector fragment. Plasmids were transfected 
into 293TrexhZAP2 cells with Lipofectamine 2000 (Invit-
rogen) according to the manufacturer’s protocol.
To produce vesicular stomatitis virus envelope glyco-
protein (VSV-G) pseudotyped HIV-1 virus, HEK293T 
cells were cotransfected with plasmids pMDG (plasmid 
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expressing VSV-G) and pNL4.3Env−Luc+ (based on 
HIV-1 provirus pNL4.3 with Firefly luciferase gene 
inserted into Nef gene and two frameshifts rendering 
the clone Env− and Vpr−) by Calcium Phosphate trans-
fection method. VSV-G pseudotyped Moloney Murine 
Leukemia Virus (MoMuLV) were produced by cotrans-
fection with pMDG, pCMVintron (plasmid encoding NB 
MoMuLV gag-pol) and pFB-luc (Stratagene) (transducing 
vector expressing Firefly luciferase). VSV-G HR’CMV-luc 
in which a large portion of the HIV-1 genome is deleted 
and luciferase activity is driven by a CMV promoter 
is described in Ref. [27]. Cells were cotransfected and 
media was changed the following day. Viral supernatants 
were harvested from cells 48  h post-transfection and 
passed through a 0.45 µm pore filter. For infections, viral 
supernatants were overlaid on cells for 2 h, then replaced 
with media.
To measure firefly luciferase reporter activity, luciferase 
assay reagent (Luciferase assay system, Promega) was 
added to lysates and monitored using the POLARstar 
Omega multi-mode microplate reader (BMG Labtech). 
Protein levels of extracts were normalized by Bradford 
assay prior to measurement.
Antibodies
Mouse α-DDX17 (Santa Cruz, Santa Cruz, CA, USA), 
mouse α -Exosc3 (Santa Cruz), mouse α-c-Myc (Santa 
Cruz), mouse α-DDK (Origene, Rockville, MD, USA), 
mouse α-α-Tubulin (Sigma-Aldrich, St. Louis, MO, USA), 
mouse α-GAPDH (EMD Chemicals, Inc., San Diego, CA, 
USA), and secondary IRDye 680LT donkey polyclonal 
α-mouse IgG (H + L) (LI-COR, Lincoln, NE, USA) and 
donkey α-rabbit IgG (H&L) IRDye 800 (Rockland, Gil-
bertsville, PA, USA) were used in immunoblot analysis. 
Rabbit α-Matrin 3 (Bethyl Laboratories, Inc., Montgom-
ery, TX, USA) was used in immunoblot analysis and 
with Normal Rabbit IgG polyclonal antibody (Millipore, 
Temecula, CA, USA) in coimmunoprecipitation studies.
Immunoblot analysis and Coimmunoprecipitations
Cells were washed in cold PBS, then harvested with 
lysis buffer (20  mM Tris–HCl pH 7.5, 150  mM NaCl, 
1% NP40) and sonicated on ice in the presence of pro-
tease and phosphatase inhibitors (Roche). RNAse A 
(50  µg/ml) was added to lysates and incubated at RT 
for 1  h. Lysates were then centrifuged for 30  min at 
13,000  rpm and a sample for whole cell extract (WCE) 
was collected. The soluble fraction was then subjected to 
immunoprecipitation.
Dynabeads Protein G (Invitrogen) were washed and 
then bound to 1 µg of control rabbit IgG antibody or rab-
bit α-Matrin3 with rotation for 1.5 h at 4°C in lysis buffer. 
These were then washed four times before adding the 
beads to lysates. Antibody-bound beads were incubated 
with lysates overnight at 4°C, then washed four times 
with lysis buffer for a total of 30 min. SDS sample buffer 
was added to beads. Samples were then boiled and sepa-
rated from the beads and collected for further analysis.
Mass spectrometry
CHME3 and CHME3 cells infected with HIV-luc were 
harvested 2  days postinfection. These were lysed in 
lysis buffer (20  mM Tris–HCl pH 7.5, 150  mM NaCl, 
1% NP40) and sonicated on ice in the presence of pro-
tease and phosphatase inhibitors. Lysates were then 
centrifuged for 30  min at 13,000  rpm and the soluble 
fraction was then subjected to immunoprecipitation. 
To minimize the elution of immunoglobulins following 
immunoprecipitation, Dynabeads Protein G (Invitro-
gen) were crosslinked with 10 µg of control rabbit IgG 
antibody or rabbit α-Matrin3. Antibody bound beads 
were washed in citrate phosphate buffer, followed by a 
wash in sodium borate. Beads were then resuspended 
in 20  mM DMP in sodium borate for 30  min at 20°C. 
This was followed by a wash with TBST (TBS with 0.1% 
Tween-20). Subsequently the beads were incubated 
with lysates at 4°C, and washed with 4 times with lysis 
buffer for a total of 30 min. SDS sample buffer without 
beta mercaptoethanol was added to the beads and the 
supernatant was separated from the beads. Βeta mer-
captoethanol was then added to the supernatants and 
boiled. Samples were then briefly run on an SDS- PAGE 
gel. Samples were excised from the resolving gel and 
sent for LC–MS/MS analysis at the Protein Core facil-
ity of the Herbert Irving Comprehensive Cancer Center 
at Columbia University. LC–MS/MS analysis was done 
on a Waters Ultima Q-Tof hybrid quadrupole/time-
of-flight mass spectrometer with a nanoelectrospray 
source. Raw data files were processed using the Mass-
Lynx ProteinLynx software and .pkl files were submit-
ted for searching at www.matrixscience.com using the 
Mascot algorithm.
siRNA knockdown
siRNA against Matrin 3 (Catalog #HSS114730, Invitro-
gen, Carlsbad, CA, USA), SFPQ (Catalog #HSS109642), 
HNRNPU (Catalog #HSS104917), Lamin A (Catalog 
#HSS106095), and negative control, Stealth RNAi siRNA 
Negative Control Med GC Duplex #2 (Invitrogen, Carls-
bad, CA, USA) were used. 293TrexhZAP2 cells were 
transfected with siRNAs using Lipofectamine RNAiMAX 
(Invitrogen) according to manufacturer’s instructions. 
Transfections were performed for two consecutive days 
before infection the following day.
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Statistical analysis
The mean values ± SD from were calculated from at least 
three independent experiments unless otherwise indi-
cated. Unpaired t test were performed using GraphPad 
Prism version 6.04 Software. P values ≤0.05 were consid-
ered significant.
Quantitative real‑time RT‑PCR (qRT‑PCR) and nuclear/
cytoplasmic fractionation
Cells were separated into nuclear and cytoplasmic frac-
tions (adapted from [48]) prior to qRT-PCR analysis. 
Briefly cells were washed with PBS, followed by resus-
pension in lysis buffer [10 mM Tris 8.0, 1.5 mM MgCl2, 
140 mM NaCl, 10 mM EDTA, 0.5% NP40 and 0.3 U/ml 
RNaseOUT (Invitrogen)]. A sample was obtained for 
whole cell extract RNA. Extracts were then centrifuged 
twice at 3,000 rpm for 5 min at 4°C, and the supernatants 
containing the cytoplasmic fraction were harvested. The 
remaining nuclear pellets were washed twice with lysis 
buffer, and passed through a 20-gauge needle.
RNA was isolated from 293TrexhZAP2 WCE, nuclear 
and cytoplasmic fractions using TRIzol Reagent (Ambion 
Invitrogen). To remove potential DNA contamination, 
RNAs were DNAse treated using a TURBO DNA-free kit 
(Ambion Invitrogen). 2 µg of RNA was then reverse tran-
scribed with High-Capacity cDNA Reverse Transcription 
kit (Applied Biosystem, Foster City, CA, USA) accord-
ing to manufacturer’s instructions. RNA levels were then 
measured using FastStart Universal SYBR Green Mas-
ter (Rox). Here 3  μl of diluted cDNA, diluted primer 
and SYBR green master mix were added to a total 20 μl 
reaction and measured in the 7500 Fast Real-Time PCR 
system (Applied Biosytems) using the following PCR pro-
gram: (1) 50°C 2 min, 1 cycle (2) 95°C 10 min, 1 cycle (3) 
95°C 15 s → 60°C 1 min, 40 cycles. Target gene mRNA 
expression was normalized to GAPDH expression.
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